Open Access 01-12-2017 | Case report
Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC
Published in: World Journal of Surgical Oncology | Issue 1/2017
Login to get accessAbstract
Background
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has become a common treatment approach for disseminated appendiceal neoplasms. Systemic absorption of intraperitoneal chemotherapeutics may lead to drug-induced toxicity, most commonly neutropenia. Mitomycin C has been the most commonly used chemotherapeutic in HIPEC for the past several decades.
Case presentation
Here, we describe a rare pulmonary complication secondary to intraperitoneal administration of mitomycin C.
Conclusions
While rare, intraperitoneal mitomycin C has the potential to cause serious pulmonary toxicity that should be considered with administration. To our knowledge, this report represents only the second case described in the literature.